Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience
Campath is a humanized monoclonal antibody targeted to the CD52 antigen. It shows efficacy with response rate of 35% in treatment of patients with chronic lymphocytic leukemia (CLL) who were refractory to fludarabine. A first-line therapy with Campath demonstrates efficacy in more than 80% of CLL pa...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2022-11-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/620 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|